Company Filing History:
Years Active: 2014
Title: The Innovative Contributions of Pablo DeLeon
Introduction
Pablo DeLeon is a notable inventor based in Philadelphia, PA. He has made significant contributions to the field of therapeutic agents, particularly in the treatment of central nervous system disorders. His work focuses on developing compounds that target specific neurological and psychiatric conditions.
Latest Patents
DeLeon holds a patent for quinolinone PDE2 inhibitors. This invention is directed towards quinolinone compounds that serve as therapeutic agents for treating central nervous system disorders associated with phosphodiesterase 2 (PDE2). The compounds are particularly useful for addressing neurological and psychiatric disorders such as schizophrenia, psychosis, and Huntington's disease, as well as conditions related to striatal hypofunction or basal ganglia dysfunction. He has 1 patent to his name.
Career Highlights
Pablo DeLeon is currently employed at Merck Sharp & Dohme Corporation, a leading global healthcare company. His role involves extensive research and development in the pharmaceutical sector, where he applies his expertise to create innovative solutions for complex health issues.
Collaborations
Throughout his career, DeLeon has collaborated with several talented individuals, including Melissa S Egbertson and Ivory D Hills. These partnerships have enhanced his research efforts and contributed to the advancement of therapeutic innovations.
Conclusion
Pablo DeLeon is a distinguished inventor whose work in quinolinone PDE2 inhibitors showcases his commitment to improving treatments for central nervous system disorders. His contributions to the field are invaluable and reflect the importance of innovation in healthcare.